Christine M Blasey

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice
    Tomoko Asagami
    Department of Cardiovascular Medicine, Stanford University, Stanford, CA 94305, USA
    J Nutr Metab 2011:235389. 2011
  2. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009
  3. doi request reprint Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men
    Coleman Gross
    Corcept Therapeutics Incorporated, Menlo Park, California, USA
    Obesity (Silver Spring) 18:2295-300. 2010
  4. doi request reprint Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats
    Joseph K Belanoff
    Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94061, United States
    Eur J Pharmacol 655:117-20. 2011
  5. doi request reprint Efficacy and safety of mifepristone for the treatment of psychotic depression
    Christine M Blasey
    Corcept Therapeutics Incorporated, Menlo Park, CA, USA
    J Clin Psychopharmacol 31:436-40. 2011
  6. doi request reprint Catastrophizing, depression and pain-related disability
    Bruce A Arnow
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Gen Hosp Psychiatry 33:150-6. 2011
  7. doi request reprint Mifepristone treatment of olanzapine-induced weight gain in healthy men
    Coleman Gross
    Corcept Therapeutics, Menlo Park, CA 94025, USA
    Adv Ther 26:959-69. 2009

Collaborators

Detail Information

Publications7

  1. pmc Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice
    Tomoko Asagami
    Department of Cardiovascular Medicine, Stanford University, Stanford, CA 94305, USA
    J Nutr Metab 2011:235389. 2011
    ....
  2. doi request reprint A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction
    Christine M Blasey
    Corcept Therapeutics, 149 Commonwealth Drive, Menlo Park, CA 94025, United States
    Contemp Clin Trials 30:284-8. 2009
    ....
  3. doi request reprint Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men
    Coleman Gross
    Corcept Therapeutics Incorporated, Menlo Park, California, USA
    Obesity (Silver Spring) 18:2295-300. 2010
    ..Future research should continue to test the potential of glucocorticoid antagonists to alleviate the deleterious side effects associated with use of antipsychotic medications...
  4. doi request reprint Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats
    Joseph K Belanoff
    Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, CA 94061, United States
    Eur J Pharmacol 655:117-20. 2011
    ..Both glucocorticoid receptor antagonists significantly attenuated the weight gain induced by olanzapine in a dose dependent manner. Differences in weight gain were not attributable to decreased food intake...
  5. doi request reprint Efficacy and safety of mifepristone for the treatment of psychotic depression
    Christine M Blasey
    Corcept Therapeutics Incorporated, Menlo Park, CA, USA
    J Clin Psychopharmacol 31:436-40. 2011
    ....
  6. doi request reprint Catastrophizing, depression and pain-related disability
    Bruce A Arnow
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Gen Hosp Psychiatry 33:150-6. 2011
    ..The objective of the study was to examine catastrophizing, depression and their interactive effects in predicting disability in patients with chronic pain...
  7. doi request reprint Mifepristone treatment of olanzapine-induced weight gain in healthy men
    Coleman Gross
    Corcept Therapeutics, Menlo Park, CA 94025, USA
    Adv Ther 26:959-69. 2009
    ..The objective of this study was to determine if mifepristone, a glucocorticoid receptor antagonist, could prevent olanzapine-induced weight gain...